INS and cancer: A cohort consisted of 23,473 UK patients with insulin-treated diabetes were followed for an average of 30 years for cancer incidence and mortality compared with general population rates showed that patients with T1DM had significantly raised risks only for ovarian and vulval cancers, with the greatest risk when diabetes was diagnosed at ages 10-14 (36).